share_log

UBS Initiates Coverage On Harmony Biosciences With Buy Rating, Announces Price Target of $56

UBS Initiates Coverage On Harmony Biosciences With Buy Rating, Announces Price Target of $56

瑞銀開始覆蓋對harmony biosciences的買入評級,宣佈目標股價爲56美元
Benzinga ·  09/10 08:50  · 評級/大行評級

UBS analyst Ashwani Verma initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $56.

瑞銀分析師阿什瓦尼·維爾瑪開始對harmony biosciences(納斯達克:HRMY)進行買入評級,並宣佈目標價格爲56美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論